Physician profile
May M Antone
NPI 1194797035
$8,723.88
in general payments reported to CMS, 2019-2025
43 companies · $961 in 2025
The $961 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $1,046 · 2021: $2,197 · 2022: $1,504 · 2023: $1,138 · 2024: $958 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,057.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,927.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,219.11 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Astrazeneca Pharmaceuticals LP | $1,121.89 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $743.65 | 2019-2025 | |
| Abbvie INC. | $718.18 | 2021-2025 | Vraylar, Ubrelvy, Botox |
| Teva Pharmaceuticals USA, INC. | $497.40 | 2019-2022 | |
| Amgen INC. | $366.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $275.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Redhill Biopharma INC. | $129.36 | 2020-2021 | |
| Exact Sciences Corporation | $127.55 | 2023-2024 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $114.32 | 2021-2022 | |
| Aspira Women'S Health INC | $113.60 | 2022-2023 | Ova1 |
| Biohaven Pharmaceutical Holding Company LTD. | $108.92 | 2022 | |
| Agios Pharmaceuticals, INC. | $103.70 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $85.43 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw May Antone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.